Navigation Links
Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Date:11/6/2007

In Phase I Clinical Evaluation Anticoagulant Inhibits Clotting Factor IXa;

Matched Antidote Rapidly Reverses Anticoagulant Effect

ORLANDO, Fla., Nov. 6 /PRNewswire/ -- Regado Biosciences today presented encouraging data from Phase Ia and Phase Ib dose escalation studies of the Company's REG1 Anticoagulation System. REG1 is a two-component system consisting of an aptamer-based anticoagulant, RB006, and its matched antidote, RB007, which binds to and neutralizes RB006. The data showed RB006 completely inhibited the activity of Factor IXa, a protein essential to blood clotting, and RB006's activity was rapidly and safely reversed by RB007 in the Phase I studies. Confirming previously reported Phase I results, these data were presented at the American Heart Association's 2007 Scientific Sessions, currently being held in Orlando, Florida.

"These Phase I results are encouraging, and this system should be evaluated further in confirmatory Phase II and III clinical studies. Experienced clinicians recognize the importance of being able to titrate the intensity of anticoagulation according to specific patient needs. Current drugs do not offer an optimal level of control or flexibility," said Richard C. Becker, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute. "Should additional well-controlled clinical studies confirm these data, REG1 may have potential for broad applications in clinical practice settings from the emergency room to the operating room."

Scientists from the Duke Clinical Research Institute and Regado analyzed REG1 pharmacokinetics and dosing data from 134 subjects enrolled in two of the three Phase I studies. The Phase Ia study enrolled 84 healthy volunteers; the Phase Ib study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results of the analysis showed an int
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 XRpro Sciences, Inc., a ... and development services which features high throughput transporter ... announced financial results for the year ended December ... Chairman of XRpro Sciences commented, "We have completed ... development stage to commercial stage in large part ...
(Date:3/27/2015)... 27, 2015 According to a ... Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), ... (AF, VT, WPW) - Global Forecasts to 2019 ", published ... reach around ~$4.73 Billion by 2019 with a CAGR ... 2019. Browse   90   ma ...
(Date:3/27/2015)... MARLBOROUGH, Mass. , March 27, 2015 ... ) and privately-held MirImmune LLC, today announced ... license agreement to RXi,s novel and proprietary ... cell-based cancer immunotherapies. The collaboration has the ... and patient friendly cancer treatments that could ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... , NEW YORK, Dec. 2 ... available in its catalogue: , Electrodes for Medical ... http://www.reportlinker.com/p0164320/Electrodes-for-Medical-Devices---A-Global-Market-Perspective.html , Electrodes in electronic devices detect electrical ... created by chemical reactions. Medical application areas include blood ...
... , PALO ALTO, Calif., Dec. 2 ... 2009, Varian, Inc. filed with the U.S. Securities and Exchange Commission ... October 2, 2009. This Annual Report may be accessed through ... "SEC Filings," and then on "10-K" in the table shown. ...
Cached Medicine Technology:Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 2Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 3Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 4Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 5Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 6Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 7
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 Endure ... Yoga for functional fitness athletes. This new program matches ... specific protocol for post-workout cool down. This program utilizes ... breath control and mental focus. , Karen Lefurgy, ... started practicing yoga long before I started Crossfit® training, ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 SMI ... today announced it has launched the SM1120 MEMS based ... market. The microsensor profile at only 220um x ... maneuverability to reach challenging locations. With industry leading ... hour, the SM1120 provides a broad operating pressure range ...
(Date:3/27/2015)... Operatic contenders and their avid audience will be in ... acclaimed baritone Sherrill Milnes will be overseeing the grand ... Merion in Evanston. The event is the culmination of ... from around the country. “This is a highly-anticipated yearly ... in the country,” said Margaret Gergen, executive director of ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... Industry is a professional and in-depth study on ... market with a focus on the Chinese ... of the industry including definitions, classifications, applications and ... provided for both the international and Chinese domestic ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Smile Brands ... providers of business support services to dental groups in ... an affiliated Castle Dental office in Hendersonville, ... Hendersonville, TN 37075, this new Castle Dental office provides ... receive the latest in comprehensive, quality dental care. Hendersonville ...
Breaking Medicine News(10 mins):Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3
... Remain to Vote on the Proposed Merger, SOUTH SAN ... Dear VaxGen Stockholder, March 28th marks the date ... stockholder vote on the proposed VaxGen-Raven,merger. Your vote is important. ... votes cast in person or by proxy at the VaxGen ...
... March 20 Arthur J. Gallagher &,Co. ... Solutions, LLC,headquartered in Fort Washington, Pennsylvania. Terms ... in 2002, Healthcare Risk Solutions, LLC is ... insurance,products, associated risk mitigation consulting services and ...
... haze, scientists say , , THURSDAY, March 20 (HealthDay News) ... an important contributor to smog. , This chemical reaction ... dioxide (NO2) in "excited" states -- was long assumed ... University of California, San Diego, conclude that it,s actually ...
... Peake: Health Care Closer for Veterans, WASHINGTON, March ... access to world-class health care under,a Department of Veterans ... 2008. Secretary of Veterans Affairs Dr. James B. Peake ... Kentucky,Illinois, Indiana, Oklahoma, Tennessee and Washington., "VA is ...
... a proactive follow-up care program designed to help ... of life, PALO ALTO, Calif., March 20 ... it is offering oncology treatment,centers a way to provide ... quality of life. Varian is teaming with,Cogent Health Solutions ...
... people felt better dispersing gifts than buying things for themselves , , ... buy happiness, at least when you spend it on others. ... 21 issue of Science . It found that spending ... , What,s more, most people seemed unaware of this ...
Cached Medicine News:Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 2Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 3Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 4Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 5Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 6Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 7Health News:Smog's Origins Get Clearer 2Health News:VA to Open 14 New Clinics in Seven States 2Health News:Varian Medical Systems Teams With Cogent Health Solutions to Offer Case Management Software for Cancer Survivorship 2Health News:Varian Medical Systems Teams With Cogent Health Solutions to Offer Case Management Software for Cancer Survivorship 3Health News:Give and Be Happy 2
... Optima MAX has the highest g-force ever. ... more than force. Optima MAX combines maximum ... achieve benchtop performance that's worlds apart from ... superior design, and enhanced efficiency, Optima takes ...
... generating 694,000 x g at ... Beckman Coulter's Optima L-90K Ultracentrifuge ... separations in less time. This ... a broad range of superb ...
... chemistry system brings versatility in a ... laboratory. A model of innovation and ... system features state-of-the-art Dimension technology, specifically ... in a flexible, affordable, easy-to-use system ...
... Dimension clinical chemistry integrated systems combine the ... cartridge, the power of the Multiply and ... the heterogeneous module to meet the challenges ... broad test menus, the systems can meet ...
Medicine Products: